MedTrace Logo

The Equivalency of the Imp SFB7+ (L-Dex U400) With the Imp XCA Device

NCT00766935 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 30

Last updated 2021-08-27

No results posted yet for this study

Summary

The purpose of this project is to prove that the Imp™SFB7+ (L-Dex U400) is equivalent to the Imp™ XCA device in assessing Lymphoedema. The Imp™ XCA device is a simple device capable of assessing Lymphoedema of a single arm. The Imp™SFB7+ (L-Dex U400) is a more complex device capable of assessing Lymphoedema in a larger population of Lymphoedema sufferers. The Imp™SFB7+ (L-Dex U400) will be developed to assess patients with Lymphoedema in their arms or their legs. The Imp™ XCA and Imp™ SFB7 are both TGA approved devices. The Imp™ SFB7+ (L-Dex U400) is similar to the Imp™ SFB7 the changes are to the software and user interface.

Conditions

  • Lymphedema

Sponsors & Collaborators

  • ImpediMed Limited

    lead INDUSTRY

Principal Investigators

  • Robyn Box, PhD · Queensland Lymphoedema and Breast Oncology Physiotherapy

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2007-11-30
Primary Completion
2007-12-31
Completion
2008-04-30

Countries

  • Australia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00766935 on ClinicalTrials.gov